Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma

Liezel L Griffin; Laura Cove-Smith; Hana Alachkar; John A Radford; Rebecca Brooke; Kim M Linton

doi:10.1016/j.jdcr.2017.09.028

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma

JAAD Case Rep. 2018 Feb 23;4(3):229-231. doi: 10.1016/j.jdcr.2017.09.028. eCollection 2018 Apr.

Authors

Liezel L Griffin¹, Laura Cove-Smith^{2

3}, Hana Alachkar⁴, John A Radford^{2

3}, Rebecca Brooke¹, Kim M Linton^{2

3}

Affiliations

¹ Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
² Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom.
³ Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom.
⁴ Department of Immunology, Salford Royal NHS Foundation Trust, Salford, United Kingdom.

No abstract available

Keywords: PD-1, programmed death-1 protein; TEN, toxic epidermal necrolysis; adverse events; immune related; irAEs, immune-related adverse events; lymphoma; nivolumab; programmed death-1 inhibitor; toxic epidermal necrolysis.

Publication types

Case Reports